(Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, [email protected].

22
(Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, [email protected]

Transcript of (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, [email protected].

Page 1: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.

(Dr). Santosh Kumar Narla,Formulation Regulatory Affairs,

[email protected]

Page 2: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.

Genotoxic impurities

Impurities are unwanted chemicals, have no therapeutic value and are potentially harmful. Therefore they need to be controlled in API and DP.

Impurities can be classified into:

Organic impurities (process- and drug-related)

Inorganic impurities

Residual solvents

Genotoxic impurities

Sources of impurities:

Starting materials

By-products

Intermediates

Degradation products

Reagents, ligands and catalysts

Page 3: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.

Evidence of genotoxicity:

Genetic damage,

Cell death

neoplastic transformation.

Regulatory Expectations:

• January 2007

EMEA CHMP Guideline on the Limits of Genotoxic Impurities

• February 2008

EMEA letter requesting evaluation of sulfonic esters in all marketed products

• June 2008 and December 2009

EMEA Questions & Answers Documents on the CHMP Guideline on the Limits of

Genotoxic Impurities

• December 2008

FDA Draft Guidance for Industry: Genotoxic and Carcinogenic Impurities in Drug

Substances and Products; Recommended Approaches

Page 4: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.

Genotoxic potential “alert structures”

Page 5: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.

Genotoxins: EMEA/CHMP/QWP/251344/2006

•Are considered unsafe at any level.

•A limit for a genotoxin with an understood toxicity can be calculated based

upon the known PDE.

•A limit for a genotoxin without sufficient toxicity information must determine

based upon a TTC of 1.5 ug/day.

Max limit = TTC/maximum dose.

•Levels above this limit need to justified toxicologically.

•Limits for genotoxins like aflatoxins, N-nitroso-, and azoxy-compounds are

considered so toxic they must be justified using toxicological study data.

TTC = Threshold of Toxological Concern

Page 6: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.

ADI and Daily Dose

“A Rationale for Determining, Testing and Controlling Specific Impurities in Pharmaceuticals that Possess Potential for Genotoxicity”, Mueller, et al., Regulatory Toxicology and Pharmacology44(2006) 188-211.

Page 7: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.

Categorization, Qualification and Risk Assessment

Page 8: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.
Page 9: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.
Page 10: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.
Page 11: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.

Relationship Between Staged TTC, Drug Dose and Impurity Concentration Limit

Page 12: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.

Assessment of Potential Genotoxic Impurities

Page 13: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.
Page 14: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.
Page 15: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.
Page 16: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.
Page 17: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.
Page 18: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.
Page 19: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.

Decision Tree

Page 20: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.
Page 21: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.
Page 22: (Dr). Santosh Kumar Narla, Formulation Regulatory Affairs, santosh_narla@yahoo.com.